查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301143

痛風治療藥物市場規模、份額、趨勢分析報告：按類別、按疾病、按分銷渠道、按地區、細分趨勢：2023-2030

Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease Condition (Acute, Chronic), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

痛風治療市場增長和趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年，全球痛風藥物市場將達到41.3億美元，2023年至2030年復合年增長率為6.25%。

市場發展是由日益增加的全球疾病負擔、政府和私人組織為提高公眾意識所做的努力以及該領域新療法的最新發展推動的。此外，臨床管線藥物數量的增加也帶來了利潤豐厚的市場增長機會。

在全球範圍內，痛風的患病率正在增加，這是推動市場增長的關鍵因素。例如，Elsevier的一篇論文報告稱，2021年，澳大利亞痛風患病率將在1.5%至2.9%之間。同樣，2021 年，加拿大和英國報告的疾病病例分別增加了約 4% 和 2.33%。老年人口數量的增加、酒精和果糖攝入量等不良飲食習慣、久坐生活方式的增加以及腎功能不全、心血管疾病和糖尿病等合併症進一步支持了這種高患病率。我在這裡。

強大的臨床試驗管道和預期的新療法推出預計將在預測期內推動市場增長。目前，Jiangsu HengRui Medicine Co, Ltd.的SHR4640等候選新藥正處於治療痛風的3期臨床試驗中。同樣，2023 年 3 月，Selecta Biosciences, Inc. 宣布了 SEL-212 3 期 DISSOLVE I 和 II 安慰劑對照隨機臨床試驗的積極結果。SEL-212適用於慢性頑固性痛風。

主要參與者正在做出聯合研究、併購、合同和金融投資等戰略努力，以推動市場的增長。例如，2021 年 6 月，Horizon Therapeutics plc 與 Arrowhead Pharmaceuticals 合作開發一種潛在的 RNAi 療法，用於治療不受控制的痛風。2022年7月，該公司獲得 FDA 對 Krystexxa 的擴大批准，用於治療未受控制的痛風患者。該藥物與免疫療法和化療藥物甲氨蝶呤一起使用。

此外，2023 年 3 月，Horizon 發起了全國腎臟月活動“Weed it G'out”。該活動利用鮮花和雜草來關聯尿酸對腎臟的影響。該活動旨在提高人們對痛風的認識，鼓勵人們認真對待痛風並尋求專業幫助。

痛風治療市場報告亮點

  • 由於高處方率、低成本和強大的市場佔有率，非甾體抗炎藥 (NSAID) 細分市場在 2022 年佔據最大的市場份額。
  • 按疾病劃分，由於患者數量高於慢性病，因此到 2022 年，急性病細分市場將佔總市場份額的 65.77%
  • 2022年，零售藥店佔據該領域最高的細分市場份額。然而，在線藥店將在預測期內增長最快
  • 由於痛風患病率上升、個人對疾病治療的認識較高以及該地區獲得良好的醫療保健等因素，北美在 2022 年將主導全球市場。
  • 該領域的領先公司包括 GlaxoSmithKline plc、Takeda Pharmaceutical Company Ltd.、Regeneron Pharmaceuticals Inc、Novartis AG、AstraZeneca plc、Merck & Co. Inc.、Teijin Ltd.、Horizon Pharma plc 和 Zydus Group。

目錄

第一章 調查方法和範圍

  • 市場細分
    • 估計/預測時間表
  • 市場定義
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • 次要信息
    • 初步調查
    • 初步調查詳情
  • 信息或數據分析
    • 數據分析模型
  • 市場形成和驗證
  • 型號詳情
    • 產品流向分析
  • 區域市場：計算複合年增長率
  • 調查假設
  • 二級信息列表
  • 縮略語表
  • 目的

第二章執行摘要

  • 市場快照
  • 藥物類別和病情細分的快照
  • 分銷渠道細分快照
  • 競爭格局的快照

3.全球痛風治療市場變量、趨勢和範圍

  • 痛風治療市場前景展望
    • 母公司市場展望
  • 繪製採用和增長前景圖
  • 監管框架
  • 市場驅動力分析
    • 痛風患病率上升
    • 強大的研發管線帶來先進的新療法
    • 提高公眾意識
  • 市場約束因素分析
    • 發展中國家和欠發達國家的疾病診斷延遲
  • 波特五力分析
  • 管道分析

4 痛風藥物市場：細分分析，按藥物類別，2018-2030（百萬美元）

  • 全球痛風治療市場：藥物類別變化分析
  • 非甾體抗炎藥
    • 2018-2030 年非甾體抗炎藥市場估計和預測（百萬美元）
  • 皮質類固醇
    • 2018-2030 年皮質類固醇市場估計和預測（百萬美元）
  • 秋水仙鹼
    • 2018-2030 年秋水仙鹼市場估計和預測（百萬美元）
  • 降尿酸劑
    • 降尿酸劑市場估計和預測，2018-2030 年（百萬美元）
  • 其他
    • 2018-2030 年其他市場估計和預測（百萬美元）

第五章 痛風藥物：按疾病分類分析，2018-2030（百萬美元）

  • 全球痛風治療市場：疾病變異分析
  • 急性痛風
    • 2018-2030 年急性痛風市場估計和預測（百萬美元）
  • 慢性痛風
    • 2018-2030 年慢性痛風市場估計和預測（百萬美元）

6 痛風藥物市場：2018-2030 年按分銷渠道細分分析（百萬美元）

  • 全球痛風治療市場：分銷渠道變化分析
  • 醫院藥房
    • 2018-2030 年醫院藥房市場估計和預測（百萬美元）
  • 零售藥店
    • 2018-2030 年零售藥房市場估計和預測（百萬美元）
  • 網上藥店
    • 2018-2030 年在線藥房市場估計和預測（百萬美元）

7. 痛風治療市場：2018-2030 年按地區細分分析（百萬美元）

  • 痛風治療市場：區域差異分析
    • 定義和範圍
  • 北美
    • 北美，SWOT 分析
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲，SWOT分析
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 亞太地區，SWOT分析
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲，SWOT分析
    • 墨西哥
    • 巴西
    • 阿根廷
  • MEA
    • 中東和非洲，SWOT 分析
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第8章 競爭格局

  • 上市公司
    • 公司市場分析
    • 競爭儀錶盤分析
    • 戰略框架
  • 民營企業
    • 關鍵初創企業/技術顛覆者/創新者名單
    • 區域網絡圖
  • 公司簡介
    • Takeda Pharmaceutical Company Ltd.
    • Novartis Ag
    • Regeneron Pharmaceuticals Inc.
    • Astrazeneca Plc
    • Horizon Therapeutics Plc
    • Merck &Co. Inc
    • Zydus Group
    • Teijin Ltd
    • Glaxosmithkline Plc
Product Code: GVR-1-68038-717-9

Gout Therapeutics Market Growth & Trends

The global gout therapeutics market size is expected to reach USD 4.13 billion by 2030 and expand at a CAGR of 6.25% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights

  • NSAIDs segment accounted for the largest share of the market in 2022 due to the high prescription rate, low cost, and strong presence in the market.
  • Based on disease condition, the acute condition segment held 65.77% of the total market share in 2022, owing to a high patient pool compared to the chronic condition
  • In 2022, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
  • North America dominated the global market in 2022 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region
  • Some key players in the space include GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd.; Regeneron Pharmaceuticals Inc; Novartis AG; AstraZeneca plc; Merck & Co. Inc.; Teijin Ltd.; and Horizon Pharma plc; Zydus Group and others

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Market Definitions
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Secondary Sources
    • 1.4.3 Primary Research
    • 1.4.4 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-Wise Market Estimation Using The Bottom-Up Approach
  • 1.8 Regional Market: Cagr Calculation
  • 1.9 Research Assumptions
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations
  • 1.12 Objectives
    • 1.12.1 Objective 1
    • 1.12.2 Objective 2

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Drug Class And Disease Condition Segment Snapshot
  • 2.3 Distribution Chanel Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Global Gout Therapeutics Market Variables, Trends, & Scope

  • 3.1 Gout Therapeutics Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Regulatory Framework
  • 3.4 Market Driver Analysis
    • 3.4.1 Rising Prevalence Of Gout
    • 3.4.2 Advanced And New Therapies With Strong R&D Pipeline
    • 3.4.3 Rising Awareness Among People
  • 3.5 Market Restraint Analysis
    • 3.5.1 Delayed Disease Diagnosis In Developing And Underdeveloped Countries
  • 3.6 Porter's Five Forces Analysis
  • 3.7 Pipeline Analysis

Chapter 4 Gout Therapeutics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

  • 4.1 Global Gout Therapeutics Market: Drug Class Movement Analysis
  • 4.2. Nsaids
    • 4.2.1. Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Corticosteroids
    • 4.3.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Colchicine
    • 4.4.1 Colchicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Urate-Lowering Agents
    • 4.5.1 Urate-Lowering Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Gout Therapeutics - Segment Analysis, By Disease Condition, 2018 - 2030 (USD Million)

  • 5.1. Global Gout Therapeutics Market: Disease Condition Movement Analysis
  • 5.2. Acute Gout
    • 5.2.1. Acute Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Chronic Gout
    • 5.3.1. Chronic Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Gout Therapeutics Market- Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Gout Therapeutics Market: - Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Gout Therapeutics Market: Regional Movement Analysis
    • 7.1.1 Definition & Scope
  • 7.2 North America
    • 7.2.1 North America, Swot Analysis
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Target Disease Prevalence
      • 7.2.2.4 Competitive Scenario
      • 7.2.2.5 Regulatory Framework
      • 7.2.2.6 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Target Disease Prevalence
      • 7.2.3.4 Competitive Scenario
      • 7.2.3.5 Regulatory Framework
      • 7.2.3.6 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe, Swot Analysis
    • 7.3.2 Uk
      • 7.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Target Disease Prevalence
      • 7.3.2.4 Competitive Scenario
      • 7.3.2.5 Regulatory Framework
      • 7.3.2.6 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Target Disease Prevalence
      • 7.3.3.4 Competitive Scenario
      • 7.3.3.5 Regulatory Framework
      • 7.3.3.6 Reimbursement Scenario
    • 7.3.4 France
      • 7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Target Disease Prevalence
      • 7.3.4.4 Competitive Scenario
      • 7.3.4.5 Regulatory Framework
      • 7.3.4.6 Reimbursement Scenario
    • 7.3.5 Italy
      • 7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Target Disease Prevalence
      • 7.3.5.4 Competitive Scenario
      • 7.3.5.5 Regulatory Framework
      • 7.3.5.6 Reimbursement Scenario
    • 7.3.6 Spain
      • 7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Target Disease Prevalence
      • 7.3.6.4 Competitive Scenario
      • 7.3.6.5 Regulatory Framework
      • 7.3.6.6 Reimbursement Scenario
    • 7.3.7 Sweden
      • 7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Target Disease Prevalence
      • 7.3.7.4 Competitive Scenario
      • 7.3.7.5 Regulatory Framework
      • 7.3.7.6 Reimbursement Scenario
    • 7.3.8 Denmark
      • 7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Target Disease Prevalence
      • 7.3.8.4 Competitive Scenario
      • 7.3.8.5 Regulatory Framework
      • 7.3.8.6 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Target Disease Prevalence
      • 7.3.9.4 Competitive Scenario
      • 7.3.9.5 Regulatory Framework
      • 7.3.9.6 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific, Swot Analysis
    • 7.4.2 India
      • 7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Target Disease Prevalence
      • 7.4.2.4 Competitive Scenario
      • 7.4.2.5 Regulatory Framework
      • 7.4.2.6 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Target Disease Prevalence
      • 7.4.3.4 Competitive Scenario
      • 7.4.3.5 Regulatory Framework
      • 7.4.3.6 Reimbursement Scenario
    • 7.4.4 Japan
      • 7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Target Disease Prevalence
      • 7.4.4.4 Competitive Scenario
      • 7.4.4.5 Regulatory Framework
      • 7.4.4.6 Reimbursement Scenario
    • 7.4.5 Australia
      • 7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Target Disease Prevalence
      • 7.4.5.4 Competitive Scenario
      • 7.4.5.5 Regulatory Framework
      • 7.4.5.6 Reimbursement Scenario
    • 7.4.6 South Korea
      • 7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Target Disease Prevalence
      • 7.4.6.4 Competitive Scenario
      • 7.4.6.5 Regulatory Framework
      • 7.4.6.6 Reimbursement Scenario
    • 7.4.7 Thailand
      • 7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Target Disease Prevalence
      • 7.4.7.4 Competitive Scenario
      • 7.4.7.5 Regulatory Framework
      • 7.4.7.6 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America, Swot Analysis
    • 7.5.2 Mexico
      • 7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Target Disease Prevalence
      • 7.5.2.4 Competitive Scenario
      • 7.5.2.5 Regulatory Framework
      • 7.5.2.6 Reimbursement Scenario
    • 7.5.3 Brazil
      • 7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Target Disease Prevalence
      • 7.5.3.4 Competitive Scenario
      • 7.5.3.5 Regulatory Framework
      • 7.5.3.6 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Target Disease Prevalence
      • 7.5.4.4 Competitive Scenario
      • 7.5.4.5 Regulatory Framework
      • 7.5.4.6 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 Middle East & Africa, Swot Analysis
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Target Disease Prevalence
      • 7.6.2.4 Competitive Scenario
      • 7.6.2.5 Regulatory Framework
      • 7.6.2.6 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Target Disease Prevalence
      • 7.6.3.4 Competitive Scenario
      • 7.6.3.5 Regulatory Framework
      • 7.6.3.6 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Target Disease Prevalence
      • 7.6.4.4 Competitive Scenario
      • 7.6.4.5 Regulatory Framework
      • 7.6.4.6 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Target Disease Prevalence
      • 7.6.5.4 Competitive Scenario
      • 7.6.5.5 Regulatory Framework
      • 7.6.5.6 Reimbursement Scenario

Chapter 8 Competitive Landscape

  • 8.1 Public Companies
    • 8.1.1 Company Market Position Analysis
    • 8.1.2 Competitive Dashboard Analysis
    • 8.1.3 Strategic Framework
  • 8.2 Private Companies
    • 8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
    • 8.2.2 Regional Network Map
  • 8.3 Company Profiles
    • 8.3.1 Takeda Pharmaceutical Company Ltd.
      • 8.3.1.1 Company Overview
      • 8.3.1.2 Financial Performance
      • 8.3.1.3 Product Benchmarking
      • 8.3.1.4 Strategic Initiatives
    • 8.3.2 Novartis Ag
      • 8.3.2.1 Company Overview
      • 8.3.2.2 Financial Performance
      • 8.3.2.3 Product Benchmarking
      • 8.3.2.4 Strategic Initiatives
    • 8.3.3 Regeneron Pharmaceuticals Inc.
      • 8.3.3.1 Company Overview
      • 8.3.3.2 Financial Performance
      • 8.3.3.3 Product Benchmarking
      • 8.3.3.4 Strategic Initiatives
    • 8.3.4 Astrazeneca Plc
      • 8.3.4.1 Company Overview
      • 8.3.4.2 Financial Performance
      • 8.3.4.3 Product Benchmarking
      • 8.3.4.4 Strategic Initiatives
    • 8.3.5 Horizon Therapeutics Plc
      • 8.3.5.1 Company Overview
      • 8.3.5.2 Financial Performance
      • 8.3.5.3 Product Benchmarking
      • 8.3.5.4 Strategic Initiatives
    • 8.3.6 Merck & Co. Inc
      • 8.3.6.1 Company Overview
      • 8.3.6.2 Financial Performance
      • 8.3.6.3 Product Benchmarking
      • 8.3.6.4 Strategic Initiatives
    • 8.3.7 Zydus Group
      • 8.3.7.1 Company Overview
      • 8.3.7.2 Financial Performance
      • 8.3.7.3 Product Benchmarking
      • 8.3.7.4 Strategic Initiatives
    • 8.3.8 Teijin Ltd
      • 8.3.8.1 Company Overview
      • 8.3.8.2 Financial Performance
      • 8.3.8.3 Product Benchmarking
      • 8.3.8.4 Strategic Initiatives
    • 8.3.9 Glaxosmithkline Plc
      • 8.3.9.1 Company Overview
      • 8.3.9.2 Financial Performance
      • 8.3.9.3 Product Benchmarking
      • 8.3.9.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 List of Parameters
  • Table 4 List of Distributors
  • Table 5 Global Gout Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • Table 6 Global Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 7 Global Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 8 Global Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 North America Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 10 North America Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 North America Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 12 North America Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 14 U.S. Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 15 U.S. Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Canada Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Canada Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 18 Canada Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Europe Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 22 Europe Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 Germany Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 25 Germany Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 27 UK Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 28 UK Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 30 France Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 31 France Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Italy Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 34 Italy Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Spain Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 37 Spain Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Denmark Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 40 Denmark Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Sweden Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 43 Sweden Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 Norway Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 46 Norway Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Japan Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 53 Japan Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 China Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 55 China Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 56 China Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 58 India Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 59 India Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 61 South Korea Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 62 South Korea Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 64 Australia Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 65 Australia Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Thailand Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 68 Thailand Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 71 Latin America Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 72 Latin America Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 74 Brazil Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 75 Brazil Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Mexico Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 77 Mexico Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 78 Mexico Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 80 Argentina Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 81 Argentina Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 South Africa Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 90 South Africa Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 91 South Africa Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 UAE Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 93 UAE Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 94 UAE Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & Forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market summary
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Market restraint relevance analysis (Current & future impact)
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Gout therapeutics market - PESTLE analysis
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Gout therapeutics market outlook key takeaways
  • Fig. 16 Gout therapeutics market: Drug class movement analysis
  • Fig. 17 Global gout therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Fig. 18 Global gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 19 Global NSAIDs market, 2018 - 2030 (USD Million)
  • Fig. 20 Global corticosteroids market, 2018 - 2030 (USD Million)
  • Fig. 21 Global colchicine market, 2018 - 2030 (USD Million)
  • Fig. 22 Global urate-lowering agents market, 2018 - 2030 (USD Million)
  • Fig. 23 Global gout therapeutics market: Disease condition movement analysis
  • Fig. 24 Global gout therapeutics market, by disease condition, 2018 - 2030 (USD Million)
  • Fig. 25 Global acute gout market, 2018 - 2030 (USD Million)
  • Fig. 26 Global chronic gout market, 2018 - 2030 (USD Million)
  • Fig. 27 Global gout therapeutics market: Distribution Channel movement analysis
  • Fig. 28 Global gout therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Fig. 29 Global retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 30 Global hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 31 Global online pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 32 Regional market: Key takeaways
  • Fig. 33 Gout therapeutics market regional outlook, 2018 & 2030
  • Fig. 34 North America gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 UK gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 40 France gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway gout therapeutics market, 2018 - 2030 (USD Million
  • Fig. 46 Asia Pacific gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 China gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 India gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia gout therapeutics market, 2018 - 2030 (USD Million
  • Fig. 52 Thailand gout therapeutics market, 2018 - 2030 (USD Million
  • Fig. 53 Latin America gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East Africa gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE gout therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait gout therapeutics market, 2018 - 2030 (USD Million
  • Fig. 62 Strategy frameworks